BRIEF—Ventyx rockets on reports of Lilly buyout

7 January 2026

US biotech Ventyx Biosciences’ shares surged more than 62% in post-market trading on Tuesday after The Wall Street Journal reported that the company is in advanced talks to be acquired by Eli Lilly in a deal valued at over $1 billion.

The Journal, citing people familiar with the matter, noted that a deal for Ventyx - which develops medicines to treat inflammatory diseases - could be announced imminently.

A potential buyout of Ventyx would add drugs for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis to Lilly's portfolio, along with treatments for conditions like Parkinson's disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK